| Budget Amount *help |
¥91,520,000 (Direct Cost: ¥70,400,000、Indirect Cost: ¥21,120,000)
Fiscal Year 2021: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2019: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2018: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2017: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
|
|---|
| Outline of Final Research Achievements |
Recent studies indicated the mortality in patients with acute kidney injury (AKI) is high in infectious disease. We performed single-cell transcriptome analysis and identified a novel cell population in infection related AKI model. Moreover, we explored the association between bacterial gene mutation and clinical manifestation of infectious diseases. Attachment and biofilm related genes were associated with clinical manifestation and could be novel targets for anti-microbiotics. In addition, D-Serine and D-Alanine, those are metabolites of gut microbiota, have reno-protecive roles in AKI. These findings suggested that bacteria and related metabolites are novel therapeutic target in AKI.
|
